Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Jonathan Goodman , president and CEO of newly formed company Knight Therapeutics in his new space in Montreal, Feb. 28, 2014.

Knight Therapeutics Inc., the drug distribution company created earlier this year by former Paladin Labs Inc. boss Jonathan Goodman, has pocketed $125-million (U.S.) by selling a certificate that allows companies to speed up the U.S. Food and Drug Administration's approval process.

Montreal-based Knight was set up by Mr. Goodman in the spring after he sold Paladin for roughly $3-billion. He started the new firm with just one drug that was transferred from Paladin – a treatment for the tropical disease leishmaniasis.

That product, Impavido, came with a bonus: a rare "priority review voucher" that was created by the FDA to encourage companies to develop new treatments for tropical and pediatric diseases. Only four of the transferable vouchers, which guarantee the FDA will fast-track any future drug's approval process, have been issued since the program began in 2007.

Story continues below advertisement

Knight had no intention of using the voucher itself – it wants to distribute existing specialty drugs, not create new ones – so it began looking for a buyer in August. It hired an investment bank to set up an auction.

Mr. Goodman said it was not at all clear how much Knight could expect to get for its certificate. Only one had changed hands before, for $67.5-million. But the value can vary dramatically depending on how urgently a company wants to get a new product to market. The voucher cuts about four months off the FDA review process, and that can be hugely valuable for a new drug that could potentially generate billions of dollars of sales.

Mr. Goodman said in an interview Wednesday that there were "a handful" of interested buyers, and that created a bit of a bidding war.

The winning bidder for Knight's certificate was Gilead Sciences Inc., a global pharmaceuticals company based in California. It makes a wide range of drugs, including treatments for cancer, liver diseases and HIV/AIDS.

Gilead spokesman Nathan Kaiser said there are "a number of potential clinical candidates in our pipeline" where the voucher could be helpful. "We will make the decision to apply the [voucher] in conjunction with ongoing internal pipeline reviews," he said.

Knight will add the money from the sale to its growing cash resources, which stood at $227-million (Canadian) as of Sept. 30. "This gives us more possibilities to grow the business faster," Mr. Goodman said. The company is looking at dozens of potential transactions, he said, including drug distribution deals, company acquisitions, secured loans to other companies, and investments in life science funds.

Analyst Leon Aghazarian, of National Bank Financial, said Knight got a lot more for the voucher than he had expected. His prediction had been for a sale price of $75-million. The more lucrative proceeds will "further increase Knight's already rock-solid financial position," he said in a report.

Story continues below advertisement

Knight share price rose more than 8 per cent Wednesday, to close at $6.53 a share. Mr. Aghazarian, who has an "outperform" rating on the stock, raised his 12-month target to $7 from $6.50.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies